Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $55,693 | 33 | 48.6% |
| Food and Beverage | $38,440 | 1,841 | 33.5% |
| Travel and Lodging | $8,680 | 21 | 7.6% |
| Consulting Fee | $7,310 | 2 | 6.4% |
| Honoraria | $4,000 | 2 | 3.5% |
| Education | $511.30 | 9 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $67,253 | 282 | $0 (2024) |
| ViiV Healthcare Company | $14,007 | 310 | $0 (2024) |
| Napo Pharmaceuticals Inc | $5,393 | 33 | $0 (2024) |
| Theratechnologies Inc. | $2,769 | 35 | $0 (2024) |
| Janssen Products, LP | $2,365 | 9 | $0 (2021) |
| ABBVIE INC. | $2,354 | 136 | $0 (2024) |
| EMD Serono, Inc. | $2,284 | 132 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,801 | 99 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,601 | 74 | $0 (2024) |
| Lilly USA, LLC | $1,400 | 74 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,034 | 257 | ViiV Healthcare Company ($1,710) |
| 2023 | $4,495 | 212 | ViiV Healthcare Company ($967.86) |
| 2022 | $13,011 | 189 | Gilead Sciences, Inc. ($5,361) |
| 2021 | $10,610 | 161 | Gilead Sciences, Inc. ($5,188) |
| 2020 | $7,085 | 190 | Gilead Sciences, Inc. ($3,903) |
| 2019 | $29,909 | 300 | Gilead Sciences, Inc. ($25,585) |
| 2018 | $24,400 | 309 | Gilead Sciences, Inc. ($17,932) |
| 2017 | $19,090 | 290 | Gilead Sciences Inc ($8,430) |
All Payment Transactions
1,908 individual payment records from CMS Open Payments — Page 1 of 77
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/26/2024 | ViiV Healthcare Company | RUKOBIA (Drug) | Food and Beverage | In-kind items and services | $29.63 | General |
| Category: HIV | ||||||
| 12/20/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $9.22 | General |
| Category: HIV | ||||||
| 12/20/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $9.08 | General |
| 12/19/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $25.35 | General |
| Category: Diabetes | ||||||
| 12/19/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $9.00 | General |
| 12/19/2024 | Theratechnologies Inc. | EGRIFTA (Drug), TROGARZO | Food and Beverage | In-kind items and services | $8.66 | General |
| Category: HIV | ||||||
| 12/18/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $31.77 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 12/18/2024 | Theratechnologies Inc. | EGRIFTA (Drug), TROGARZO | Food and Beverage | In-kind items and services | $4.90 | General |
| Category: HIV | ||||||
| 12/12/2024 | Antares Pharma, Inc. | XYOSTED (Drug) | Food and Beverage | In-kind items and services | $26.78 | General |
| Category: TESTOSTERONE REPLACEMENT THERAPY | ||||||
| 12/12/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $6.68 | General |
| Category: PAIN | ||||||
| 12/11/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $28.72 | General |
| 12/10/2024 | Napo Pharmaceuticals Inc | Mytesi (Drug) | Food and Beverage | Cash or cash equivalent | $24.63 | General |
| Category: Infectious Disease | ||||||
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $18.82 | General |
| 12/04/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $33.72 | General |
| Category: PSYCHIATRY | ||||||
| 12/04/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $31.52 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $7.44 | General |
| Category: Diabetes | ||||||
| 12/03/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $34.28 | General |
| 12/03/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $10.50 | General |
| Category: HIV | ||||||
| 11/28/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $6.69 | General |
| Category: Diabetes | ||||||
| 11/27/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $10.25 | General |
| 11/26/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug), DELSTRIGO | Food and Beverage | In-kind items and services | $28.77 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/26/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $6.34 | General |
| 11/22/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $26.16 | General |
| Category: PAIN | ||||||
| 11/22/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $7.41 | General |
| Category: HIV | ||||||
| 11/21/2024 | ABBVIE INC. | VIBERZI (Drug), CREON | Food and Beverage | In-kind items and services | $16.19 | General |
| Category: GASTROENTEROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 601 | 841 | $227,998 | $74,790 |
| 2022 | 9 | 533 | 822 | $175,603 | $69,425 |
| 2021 | 8 | 399 | 559 | $102,255 | $53,130 |
| 2020 | 8 | 318 | 495 | $86,495 | $39,658 |
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 208 | 371 | $107,854 | $34,562 | 32.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 143 | 197 | $42,712 | $12,267 | 28.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 58 | 73 | $32,573 | $9,430 | 29.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 43 | 43 | $13,542 | $5,984 | 44.2% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 13 | 13 | $7,505 | $3,673 | 48.9% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 37 | 37 | $8,173 | $2,799 | 34.3% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2023 | 12 | 12 | $4,871 | $2,116 | 43.4% |
| G0181 | Physician or allowed practitioner supervision of a patient receiving medicare-covered services provided by a participating home health agency (patient not present) requiring complex and multidisciplinary care modalities involving regular physician or allow | Office | 2023 | 13 | 21 | $5,260 | $1,840 | 35.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 45 | 45 | $4,009 | $1,486 | 37.1% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 13 | 13 | $864.45 | $429.39 | 49.7% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 16 | 16 | $634.64 | $202.08 | 31.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 178 | 358 | $87,641 | $31,678 | 36.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 135 | 224 | $42,112 | $13,844 | 32.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 44 | 59 | $23,989 | $7,426 | 31.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 37 | 37 | $7,956 | $5,320 | 66.9% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2022 | 19 | 19 | $5,795 | $5,300 | 91.5% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2022 | 37 | 37 | $2,706 | $2,595 | 95.9% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 44 | 45 | $2,225 | $1,516 | 68.1% |
| G0009 | Administration of pneumococcal vaccine | Office | 2022 | 28 | 28 | $1,298 | $949.49 | 73.2% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 11 | 15 | $1,881 | $795.73 | 42.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 144 | 251 | $53,206 | $25,749 | 48.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 50 | 70 | $19,349 | $10,066 | 52.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 82 | 115 | $16,688 | $7,787 | 46.7% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 31 | 31 | $6,472 | $4,860 | 75.1% |
| 90694 | Influenza virus vaccine, quadrivalent (aiiv4), inactivated, adjuvanted, preservative free, for injection into muscle, 0.5 ml dosage | Office | 2021 | 28 | 28 | $1,988 | $1,860 | 93.6% |
About Dr. Mark Higgins, MD
Dr. Mark Higgins, MD is a Internal Medicine healthcare provider based in San Francisco, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1134193469.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Higgins, MD has received a total of $114,634 in payments from pharmaceutical and medical device companies, with $6,034 received in 2024. These payments were reported across 1,908 transactions from 71 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($55,693).
As a Medicare-enrolled provider, Higgins has provided services to 1,851 Medicare beneficiaries, totaling 2,717 services with total Medicare billing of $237,003. Data is available for 4 years (2020–2023), covering 36 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Location San Francisco, CA
- Active Since 02/14/2006
- Last Updated 12/04/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1134193469
Products in Payments
- Biktarvy (Drug) $12,235
- Truvada (Drug) $10,761
- Descovy (Drug) $7,429
- Mytesi (Drug) $5,393
- DOVATO (Drug) $5,000
- Genvoya (Drug) $3,669
- EGRIFTA (Drug) $2,641
- PREZCOBIX (Drug) $1,099
- APRETUDE (Biological) $1,057
- TRIUMEQ (Drug) $1,049
- VRAYLAR (Drug) $917.92
- CABENUVA (Biological) $862.28
- XIFAXAN (Drug) $816.51
- Ozempic (Drug) $725.98
- FARXIGA (Drug) $628.87
- SYMTUZA (Drug) $607.31
- JULUCA (Drug) $587.64
- TRULICITY (Drug) $568.05
- RUKOBIA (Drug) $547.66
- Vascepa (Drug) $514.70
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in San Francisco
Dr. Fred Cohen, M.d, M.D
Internal Medicine — Payments: $1.6M
John Teerlink, M.d, M.D
Internal Medicine — Payments: $1.2M
Kenneth Binmoeller, Md, MD
Internal Medicine — Payments: $1.2M
Dr. Hope Rugo, Md, MD
Internal Medicine — Payments: $881,117
Dr. Steven Harris, M.d, M.D
Internal Medicine — Payments: $806,637
Dr. Kenneth Colley, Md, MD
Internal Medicine — Payments: $732,736